We develop GPCR modulators for Idiopathic Pulmonary Fibrosis (IPF) and other inflammatory and metabolic conditions
ABOUT INNOSPERA PHARMA
Innospera Pharma is a private biotech developing small-molecule GPCR modulators for chronic and fibrotic diseases. Lead asset ING-006, a next-generation GPR84 modulator, has shown strong anti-fibrotic activity in gold-standard preclinical models.
​
​A 20–40x more potent analog of PBI-4050 (three Phase 2a trials; FDA-approved Phase 3 IPF protocol), ING-006 pairs a superior pharmacological profile with an anticipated wide safety margin and tolerability.
​
​
The pipeline includes additional GPCR modulators targeting cardiometabolic and other chronic conditions.
Leadership team
Board of Directors
Pierre Laurin, BPharm, MSc
Executive Chairman and co-founder, Innospera
François Ravenelle, PhD
President and CEO, Innospera
Lyne Gagnon, PhD
CSO and co-founder, Innospera
Patricia Escoffier, PhD
Principal, Seido Capital
​
Hélène Moore, MBA
Director, Anges Québec
​
Denis Garceau, BPharm, PhD
Ex-CSO, Bellus Health
​
Hubert Sibre, LLB
Partner, Miller Thomson
​
Maxime Daigle, CPA
Board Observer, Director, Investissement Québec
Our Science
Our scientists leverage decades of experience in developing small molecule GPCR modulators to address inflammatory-driven conditions that meet three criteria:
1
Target receptors drive the severity of the selected medical condition, the disease progression or low survival rates
2
Medical condition remains an unmet medical need and has a clear regulatory pathway
3
In gold standard preclinical models, our lead drug candidates appear superior to other products used today, or that are in development.
Fibrosis Reduction & Metabolic Regulation: A Balancing Act
Balance between GPR84 and GPR40 plays a significant role in the modulation of the fibrotic and metabolic processes.
Our library of small molecule modulators allows us to re-establish a more favourable GPR84 / GPR40 balance.
Our Lead Product: ING-006
THE IPF
OPPORTUNITY
Low life expectancy
3 to 5 years post diagnosis.
Dire unmet need
Standard of care products slow down IPF only.
Tolerability issues
Low 26.4% adoption rate due to GI adverse events.
3M adults affected worldwide
~140k in the US (rare disease).
OUR TARGET:
GPR84
Well-documented target
Vast preclinical and clinical data in inflammation and fibrosis.
Upregulated in IPF
GPR84 expression increases as a function of the severity of the disease.
ING-006 is a first-in-class GPR84 modulator
Differs from previous GPR84 antagonist programs.
​
​
​
​
SUPERIOR
DMPK
Rapid absorption/distribution
Lipid-mimetic design enables fast uptake and efficient distribution to lung tissue.
Cmax-driven pharmacodynamics
Allows low systemic burden and provides built-in safety and tolerability
Combination-ready candidate
Profile allows broad compatibility with other IPF products
​
​
​
​
​
An attractive product profile
A once-daily oral administration of an anticipated well-tolerated drug, with a differentiated MoA (first-in-class GPR84 modulator).
​
Combining efficacy with safety and tolerability
Unlike standards of care and most products in development that have important tolerability issues, we anticipate ING-006 will provide an efficacious treatment that preserves patients’ quality of life.
Our Pipeline
ING-008 and ING-Series: Expanding the Lipid-Mimetic Platform
Next-Generation Lipid-Mimetics
Analogues of prior clinical and preclinical fatty acid products, designed with differentiated GPCR modulation and unique DMPK properties.
Organ- and Indication-Specific Potential
Opportunity to target new tissues and diseases while maintaining the strong safety/tolerability profile of the class.
Pipeline Expansion
Multiple candidates under evaluation in cardiometabolic diseases, including obesity and MASH.